Effect of ombitasvir/ paritaprevir/ritonavir (ombitasvir/ABT-450/r) and dasabuvir with or without ribavirin (RBV) co-administered with raltegravir, rilpivirine, emtricitabine + tenofovir and efavirenz in healthy subjects.

Trial Profile

Effect of ombitasvir/ paritaprevir/ritonavir (ombitasvir/ABT-450/r) and dasabuvir with or without ribavirin (RBV) co-administered with raltegravir, rilpivirine, emtricitabine + tenofovir and efavirenz in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2015

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine/tenofovir disoproxil fumarate; Raltegravir; Rilpivirine
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Most Recent Events

    • 27 Feb 2015 Status changed from not stated to completed.
    • 17 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top